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Abstract  
BACKGROUND: Goodpasture syndrome was originally described as an association of alveolar 
haemorrhage and glomerulonephritis. It occurs when the immune system attacks and destroys 
healthy body tissue.  
AIM: We are presenting a patient with a clinical picture of pulmonary haemorrhage and 
glomerulonephritis, which is diagnosed by renal biopsy.  
CASE PRESENTATION: His illness began a year and a half before being diagnosed. In that period 
he had occasional exacerbations. He was received at our Clinic in extremely serious condition, and 
after stabilisation of his medical condition, there was made a biopsy of the kidney. The p-ANCA was 
8.93 U/ml (neg < 3, poz > 5 U/ml). Histopathological diagnosis of biopsy of the kidney was: 
Glomerulonephritis extra capillaries focalis, segmentalis et globalis. Based on this he was 
diagnosed with Goodpasture syndrome. He received corticosteroid therapy and cyclophosphamide, 
with good response to treatment, and he is currently in a stable condition, receiving only 
corticosteroid therapy. 
CONCLUSION: Goodpasture syndrome is a severe illness caused by the formation of antibodies to 
the glomerular basement membrane and alveolus with consequential damage to renal and 
pulmonary function. With current therapy, long-term survival is more than 50%. 
 
 
 
 
 
Introduction 
 
Goodpasture syndrome was originally 
described as an association of alveolar haemorrhage 
and glomerulonephritis. It occurs when the immune 
system attacks and destroys healthy body tissue, so it 
is defined as an autoimmune disease. Gender 
distribution is reported differently in different studies, 
according to some dates it is twice more in men than 
in women, and the age at presentation can range from 
the first to the ninth decade. Goodpasture syndrome is 
manufactured by rapidly progressive 
glomerulonephritis and alveolar haemorrhage in 
association with the presence of anti-glomerular 
basement membrane (anti-GBM) antibodies and 
another capillary basement membrane. Although it is 
rare, it is very severe immunological disease [1, 2]. 
Like other autoimmune conditions, the anti-
GBM disease is thought to result from an 
environmental insult in a person with genetic 
susceptibility. The human leukocyte antigen (HLA) 
serotype HLA-DR15 has been strongly associated 
with the anti-GBM disease. An initial insult to the 
pulmonary vasculature is required for exposure of the 
alveolar capillaries to the anti-GBM antibodies. 
Environmental factors that may lead to such exposure 
include the following: exposure to organic solvents or 
hydrocarbons, smoking, infection (eg, influenza A2), 
cocaine inhalation, exposure to metal dust, 
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lymphocyte depletion therapy, such as alemtuzumab, 
extracorporeal shock wave lithotripsy [3-5]. 
Symptoms: constitutional symptoms (eg, 
malaise, chills and fever, arthralgias) may precede or 
develop concurrently with pulmonary or renal 
manifestations; hemoptysis is the presenting symptom 
when the disease affects the lungs. The level of 
hemoptysis may vary and, in a small percentage of 
patients, may be absent. Other pulmonary symptoms 
include a cough, dyspnea, and shortness of breath. 
Massive pulmonary haemorrhage leading to 
respiratory failure may occur. Chest pain is present in 
less than half of the patients. Renal manifestations 
include hematuria, oedema, high blood pressure and 
eventually uremia. Significant anaemia may result 
from persistent intrapulmonary bleeding [6]. 
Physical examination findings in patients with 
the anti-GBM disease include the following: 
tachypnea, inspiratory crackles over lung bases, 
cyanosis, hepatosplenomegaly (may be present), 
hypertension (present in 20% of cases), rash, oedema 
[6]. 
Diagnosis can be established the bay 
presence of pulmonary haemorrhage, pulmonary 
radiography, kidney biopsy and positive resultants of 
anti-GBM antibodies. The treatment of this syndrome 
should be initiated as soon as possible using a 
combination of corticosteroid therapy, cytostatics and 
plasmapheresis [7]. 
 
 
Case Report 
 
The patient DS, male, born in 1967, has been 
admitted to the Clinic of Pulmonology and Allergology 
on May 15th, 2016. On inspection severely ill, 
presenting with a productive cough, expectoration 
mixed with blood, chills, and fever, which has been 
present for three days and measured increased body 
temperature up to 39
0
C. The patient has complained 
of nausea, fatigue, and chest tightness, as well. 
Formerly he had worked as a driver; presently he 
works with automobile lacquers and has a 10 pack-
year smoking history.  
He has sought medical advice at his primary 
care health practitioner since 2014 when he was 
referred to the Pulmonology Outpatient’s Clinic, 
whereas he has been prescribed antibiotics. He has 
been treated at the outpatient’s clinic on several 
occasions because of fever, nausea, and cough with 
bloody expectoration, malaise and sideropenic 
anaemia. These symptoms and signs have been 
repetitive the last year. He has been investigated at 
the Clinic of Rheumatology, suspected of the 
diagnosis of Gilbert syndrome, as well. Later he has 
been referred to a nephrologist because of the 
occurrence of proteinuria, hematuria and increased 
values of serum urea and serum creatinine. 
Therefore, a kidney biopsy has been indicated, for 
which the patient has not given his consent to be 
performed (April, the 14th, 2016). A computer 
tomography of the chest has been performed using 
intravenous contrast, with a series of scans during the 
arterial phase, with the following findings: interstitial 
fibrous changes bilaterally “ground-glass” opacities of 
the lung parenchyma, bilaterally with centrilobular 
emphysema in the proximal parts (April, the 28th, 
2016).  
The last admission has been at the 
department of infectious diseases of the clinical 
hospital in Kumanovo, and because of the severity of 
the general condition he has been referred to the 
University Clinic of Pulmonology and Allergy in May, 
the 15th, 2016. He has been admitted in a severely ill 
condition, presenting with fever (39
0
C) the last three 
days, headaches, vertigo, cough accompanied by 
hemoptysis, tachypneic, tachycardia, severe 
dyspnoea and malaise. The patient has shown 
decreased oxygen saturation (SatO2 = 50%) and 
hypoxemia (PaO2 = 6.35 kPa), anemia (Hgb = 7.9 g/L; 
Hct = 23.2%, RBC = 2.7 x 10^12/L; WBC = 16.9 x 
10^9/L), ESR = 60 mm/h, urea = 13.9 mmol/L, 
creatinine = 206 mmol/L, total proteins = 56 g/L, 
albumins = 33 g/L, Fe in serum = 8.1 mmol/L, CRP = 
134 U/L, troponins = 777 U/L, CK = 144 U/L, CK-MB = 
29 U/L, LDH = 686 U/L, proteinuria, hematuria. Chest 
X-ray found a massive, diffuse lung consolidation 
bilaterally, with reactive hila (Fig. 1, 2).  
 
Figure 1: RTG Posteranterior: Chest X-ray found a massive, diffuse 
lung consolidation bilaterally, with reactive hila 
 
Because of suspected Wegener’s disease, 
parenteral corticosteroids, antibiotics and oxygen 
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supplementation has been administered, with 
consequent improvement of the patient’s condition, 
when the patient has been referred to a kidney biopsy 
at a private clinic in Skopje. Anti-dsDNA = 2.32 U/ml 
(neg < 40, pos > 60 U/ml), Anti-MPO p-ANCA = 8.93 
U/ml (neg < 3, pos > 5 U/ml). 
 
Figure 2: RTG lateral view: Chest X-ray found a massive, diffuse 
lung consolidation, with reactive hila 
 
The histopathological findings of the kidney 
biopsy, performed in May, the 15th, 2016, where as 
follows: Microscopically the sections of the samples 
have revealed 11 glomeruli with surrounding tubular 
interstitium. Ten out of eleven glomeruli have had 
relatively preserved architectonics, without increased 
cellularity, endocapillary and extra capillary, whereas 
in one-to-two glomeruli the GBM (glomerular 
basement membrane) is slightly is chemically 
wrinkled.  
In one of the glomeruli, there has been found 
a segmental lesion of GBM collapse with synechiae in 
between the visceral and parietal epithelium. In the 
surrounding tubular interstitium, there are focuses of 
tubular atrophy and interstitial fibrosis (< 25%). The 
immunofluorescence technique carried out has shown 
linear IgG deposits along the GBM in eight out of eight 
glomeruli, whereas in two of the glomeruli there is 
globally collapsed GBM, and in another two there can 
be seen segmental epithelial proliferations with a 
slight impression of GBM. 
The diagnosis made is Extracapillary 
Glomerulonephritis, focal and segmental (2/19) and 
global (2/19). According to the above, the diagnosis of 
Goodpasture´s syndrome has been made. 
The patient has been admitted for the second 
time at the University Clinic of Nephrology, on June, 
the 7th, 20116, with the following values of the blood 
and biochemistry analyses: WBC = 15.5 х 10^9/L; 
serum urea = 11.6 mmol/L; creatinine = 137 mmol/L; 
urine: specific weight = 1014; pH = 6, proteins (+), 
glucose (-), blood (+), RBC = 4-5 in the sediment, 
WBC = 3-4 in the sediment. Anti GBM antibodies were 
negative during this hospitalization.  
Urinary tract ultrasound (June, the 9th, 2016): 
the kidneys, bilaterally are with proper size and shape, 
right: 110 x 52 mm, on the left 113 x 54 mm, with a 
granular parenchyma – 19 mm diameter, with slightly 
increased echogenicity from where the 
hypoechogenic medulla is noticeable. There is no 
stasis. The urinary bladder was without any changes. 
The prostate is oval, homogenous, weighing 
approximately 21 gramme.  
 
Figure 3: RTG Posteranterior: Chest X-ray has shown bilaterally 
pleura-diaphragmatic  adhesions, other findings are normal 
 
During the hospital admission the patient has 
been treated with immunosuppressive therapy, initially 
with high-dose methylprednisolone, 500 mg per day, 
three days in a row, with tapering the dosage, and 
using cyclophosphamide in one occasion. During the 
hospital admission, he had not had any respiratory 
symptoms, and the other parameters have been 
improving. Hence, plasmapheresis has not been 
indicated. Blood pressure measurements, as follows: 
115/80 – 126/89 mmHg, with no need of anti-
hypertensive therapy. There were noted slight 
decreases in the serum creatinine and the proteinuria 
measurements. The diuresis noted 2000 ml. The 
patient has been discharged with an improved general 
condition and prescribed the following drugs: Decortin 
60 mg, one tablet per day; Ranitidine 150 mg, twice 
per day. The follow-up examination at the University 
Clinic of Pulmonology and Allergy, performed in 
August, the 1st, 2016 has revealed a patient in good 
general condition. The blood gas analyses, as follows: 
SaO2 = 96.4%; PaO2 = 9.46 kPa; PaCO2 = 3.67 kPa, 
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normal spirometry measurements. The chest X-ray 
has shown bilaterally pleura-diaphragmatic adhesions, 
other findings were normal (Fig. 3, 4). At the moment 
the patient is stable and he is being treated with oral 
corticosteroids.  
 
 
Figure 4: RTG lateral view: Chest X-ray has  shown pleura-
diaphragmatic  adhesions, other findings are normal 
 
 
Discussion 
 
Ernest Goodpasture first described the 
disorder in 1919 [8]. He reported a case of pulmonary 
haemorrhage and glomerulonephritis during an 
influenza epidemic. In the 1950s, Krakower and 
Greenspon identified GBM as the antigen [9]. In 1967, 
Lerner, Glassock, and Dixon confirmed that the 
antibodies taken from the diseased kidneys produced 
nephritis in experimental animals [10]. The discovery 
of anti-GBM antibodies led to the understanding of the 
pathogenesis of Goodpasture syndrome. Anti-GBM 
disease is an uncommon disorder [11]. 
Careful attention to the medical history, 
physical examination, and targeted laboratory 
evaluation often suggests the underlying cause [12]. 
Our patient has been diagnosed almost after 
one year and half, after his symptoms appeared for 
the first time, when his condition became very severe, 
with breathlessness, massive haemopthises, renal 
failure, anemia, hematuria. Formerly he had worked 
as a driver; presently he works with automobile 
lacquers, and has a 10 pack-year smoking history. 
Anti-MPO p-ANCA was 8.93 U/ml (neg < 3, pos > 5 
U/ml). The diagnosis was made as an extracapillary 
glomerulonephritis, focal and segmental (2/19) and 
global (2/19). The patient on his admission on Clinic of 
pulmology and allergology has shown decreased 
oxygen saturation (SatO2 = 50%) and hypoxemia 
(PaO2 = 6.35 kPa), anemia (Hgb = 7.9 g/L; Hct = 
23.2%, RBC = 2.7 x 10^12/L; WBC = 16.9 x 10^9/L), 
ESR = 60mm/h, urea = 13.9 mmol/L, creatinine = 206 
mmol/L, total proteins = 56 g/L, albumins = 33 g/L, Fe 
in серум 8.1mmol/L, CRP = 134 U/L, troponins = 777 
U/L, CK = 144 U/L, CK-MB = 29 U/L, LDH = 686 U/L, 
proteinuria, hematuria. Chest X-ray found a massive, 
diffuse lung consolidation bilaterally, with reactive hila. 
The incidence of the anti-GBM disease is 
estimated to be 0.5-1.8 cases per million per year in 
both European white and Asian populations. It is 
responsible for 1-5% of all types of glomerulonephritis 
and for 10-20% of crescentic glomerulonephritis [13]. 
From 60-80% of patients have clinically 
apparent manifestations of pulmonary and renal 
disease, 20-40% has renal disease alone, and less 
than 10% have a disease that is limited to the lungs. 
Anti-GBM disease occurs more commonly in white 
people than in black people, but it also may be more 
common in certain ethnic groups, such as the Maoris 
of New Zealand. The age distribution is bimodal, 20-
30 years and 60-70 years. The prevalence of the 
disease is higher in men in the younger age group 
and women in the older age subgroup [13, 14]. 
A subgroup of patients is double-positive for 
anti-GBM antibodies and antineutrophilic cytoplasmic 
antibodies. The peak age incidence for this subgroup 
is 60-70 years, with a male predominance [15]. 
Patients presenting with serum creatinine 
levels greater than 4 mg/dL, oliguria, and more than 
50% crescents on renal biopsy rarely recover. They 
usually progress to end-stage renal failure that 
requires long-term dialysis. In a retrospective analysis 
of patients with the anti-GBM disease who started 
renal replacement therapy for end-stage renal disease 
(ESRD) in Australia and New Zealand (ANZDATA 
Registry), the median survival rate was 5.93 years 
with death predicted by older age and history of 
pulmonary haemorrhage. Conditions that affect the 
lung and kidney (pulmonary-renal syndromes) are 
important in the differential diagnosis. These include 
granulomatosis with polyangiitis (Wegener 
granulomatosis), systemic lupus erythematosus, 
microscopic polyangiitis, and other forms of systemic 
vasculitides. Distinguishing granulomatosis with 
polyangiitis from Goodpasture syndrome is particularly 
important. Interestingly, some patients with 
Goodpasture syndrome may present with 
antineutrophilic cytoplasmic antibodies (ANCAs), 
which are predominantly observed in patients with 
granulomatosis with polyangiitis. Pulmonary-renal 
syndromes are less commonly a manifestation of IgA-
mediated disorders (eg, IgA nephropathy or Henoch-
Schönlein purpura) and of immune complex–mediated 
renal disease (eg, essential mixed cryoglobulinemia). 
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Rarely, rapidly progressive glomerulonephritis alone 
can cause pulmonary-renal syndromes through a 
mechanism involving renal failure, volume overload, 
and pulmonary oedema with hemoptysis [16-18]. 
In the past, Goodpasture syndrome was 
usually fatal. Aggressive therapy with plasmapheresis, 
corticosteroids, and immunosuppressive agents has 
dramatically improved prognosis. With this approach, 
the 5-year survival rate exceeds 80% and fewer than 
30% of patients require long-term dialysis. In a study 
of patients admitted to intensive care units for the 
acute manifestation of small-vessel vasculitis, 
including anti-GBM disease, delayed administration of 
cyclophosphamide was associated with a higher 
mortality rate [19, 20]. 
On the Clinic of nephrology during the 
hospital admission our patient has been treated with 
immunosuppressive therapy, initially with high-dose 
methylprednisolone, 500 mg per day, three days in a 
row, with tapering the dosage, and using 
cyclophosphamide in one occasion. In this moment 
the patient is in remission with only “in one occasion 
use” of cyclophosphamide and plasmapheresis. He is 
being treated only with oral corticosteroids. The 
prognosis of this case, for now, is not so bad although 
delayed diagnose.  
In conclusion, Goodpasture syndrome is a 
severe illness caused by the formation of antibodies to 
the glomerular basement membrane and alveolus with 
consequential damage to renal and pulmonary 
function. With current therapy, long-term survival is 
more than 50%. Before, the mortality was higher than 
90%. The treatment involved corticosteroid therapy, 
cytostatic therapy and plasmapheresis. Very rarely it 
appears only with pulmonary involvement, so it can be 
concluded all cases of repeated pulmonary 
haemorrhage should raise suspicion of this syndrome.  
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